USANA Health Sciences, Inc. (NYSE:USNA) Q4 2021 Earnings Conference Call February 9, 2022 11:00 AM ET Company Participants Patrique Richards - Executive Director, Investor Relations and Business Development Kevin Guest - Chairman and Chief Executive Officer Doug Hekking - Chief Financial Officer Brent Neidig - Chief Officer and Managing Director of China Conference Call Participants Steph Wissink - Jefferies Doug Lane - Lane Research Disclaimer*: This transcript is designed to be used alongside the freely a ...

USANA Health Sciences, Inc. (NYSE:USNA) Q3 2021 Earnings Conference Call October 27, 2021 11:00 AM ET Company Participants Patrique Richards - Executive Director, IR & Business Development Kevin Guest - Chairman & CEO Douglas Hekking - CFO Jim Brown - President Conference Call Participants Douglas Lane - Lane Research Operator Good day, and welcome to the USANA Health Sciences Third Quarter Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. P ...

Financial Data and Key Metrics Changes - The company reported record net sales, earnings, and active customers with double-digit year-over-year sales growth in each region [7][10] - The sales program contributed significantly to the results, but management expects a deceleration in growth in the second half of the year [14][15] Business Line Data and Key Metrics Changes - The active nutrition line is showing strong initial performance, with plans for further rollout and product enhancements [39][42] - The company is focusing on expanding its product offerings beyond traditional nutritional vitamins to include lifestyle products [45][47] Market Data and Key Metrics Changes - The company is experiencing varied impacts from COVID-19 across different markets, with supply chain challenges noted [19][20] - Inventory levels have increased to approximately $90 million as the company prepares for potential supply chain disruptions [21] Company Strategy and Development Direction - The long-term growth strategy centers on customer growth and engagement, improving technology, and pursuing international expansion [10][11] - The company is investing in digital tools and enhancing customer experience, particularly in the Chinese market [33][38] Management Comments on Operating Environment and Future Outlook - Management acknowledges the challenges posed by COVID-19 and inflationary pressures on material costs, which may impact gross margins [23][24] - The company remains confident in its ability to manage these challenges and deliver another record year [11][24] Other Important Information - Capital expenditures for the year are expected to be in the range of $10 million to $15 million, with some delays due to supply chain issues [27] - The company is enhancing its logistics to ensure product availability in key markets [25][26] Q&A Session Summary Question: Concerns about deceleration in sales growth - Management explained that the strong sales growth was primarily driven by a short-term sales program, and a similar pattern is expected as seen in previous years [14][15][16] Question: Impact of COVID-19 on business - Management noted that the impact varies by market, with some experiencing lockdowns and others not, but overall supply chain management has been effective [19][20] Question: Update on the China shopping app - The app has been well-received, but its growth is part of a long-term strategy rather than a short-term boost [32][33] Question: Active Nutrition line performance - Initial results exceeded expectations, with plans for further product introductions and enhancements [50][54] Question: Feedback from associates on product preferences - Associates are requesting more options, particularly in bars, and the company is responding by expanding its product line [53][54]

USANA Health Sciences, Inc. (NYSE:USNA) Q1 2021 Earnings Conference Call April 28, 2021 11:00 AM ET Corporate Participants Patrique Richards - Executive Director of Investor Relations & Business Development Kevin Guest - Chairman & Chief Executive Officer Jim Brown - President Doug Hekking - Chief Financial Officer Brent Neidig - Chief Officer and Managing Director of China Conference Call Participants Doug Lane - Lane Research Sebastian Barbero - Jefferies Operator Good day, and welcome to the USANA Health ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 2, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission file number: 001-35024 _______________________________ USANA HEALTH SCIENCES, INC. (Exact name of registrant as specif ...

USANA Health Sciences, Inc. (NYSE:USNA) Q4 2020 Earnings Conference Call February 10, 2021 11:00 AM ET Company Participants Patrique Richards - Executive Director of Investor Relations & Business Development Kevin Guest - Chairman & Chief Executive Officer Jim Brown - President Doug Hekking - Chief Financial Officer Conference Call Participants David Bain - ROTH Capital Sebastian Barbero - Jefferies Doug Lane - Lane Research Ivan Feinseth - Tigress Financial Partners Operator Good day, and welcome to the US ...

® THE CELLULAR NUTRITION COMPANY Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking statements, which involve a number of risks and uncertainties and should be considered in conjunction with the cautionary statements contained in our most recent filings with the SEC. Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking s ...

Financial Data and Key Metrics Changes - The company reported record earnings per share and sales approaching $300 million for Q3 2020, driven by strong demand for nutritional products and successful incentive programs [7][9]. - The full-year guidance was raised to reflect the strong Q3 results and expectations for Q4 [9]. Business Line Data and Key Metrics Changes - A record number of active customers was achieved during the quarter, indicating strong engagement and demand for the company's products [7]. - The company successfully executed virtual conventions, which allowed for a larger audience reach compared to in-person events [8]. Market Data and Key Metrics Changes - The company noted that while China is recovering from the impacts of COVID-19, the growth has not yet reached the levels seen in 2017 and 2018, but the outlook remains positive [13][16]. - Approximately 5% of sales in the Greater China region come from Hong Kong [26]. Company Strategy and Development Direction - The company is focusing on organic growth and exploring deal flow opportunities to accelerate growth in new geographic regions and product lines [31]. - The company plans to continue leveraging virtual platforms for events, which have proven effective in reaching a broader audience [46][48]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying business strength despite the challenges posed by the COVID-19 pandemic [9]. - There is optimism about future growth, particularly in the context of product rollouts and market recovery [40][49]. Other Important Information - The company is seeing a lift in demand for products designed to support immune function, which has been a trend throughout the year [38]. - The company is considering investing in a platform for virtual meetings but is currently utilizing existing platforms like Zoom and Webex [44][48]. Q&A Session Summary Question: Insights on China and Sales Recovery - Management acknowledged the slower recovery in China but remains confident in the market's potential and is actively engaging in promotions to revitalize sales [12][18]. Question: Impact of COVID-19 on Margins - Management noted that while there were higher incentives and costs, lower SG&A expenses due to the absence of global conventions helped maintain margins [20][22]. Question: Capital Allocation and Share Buybacks - The company prioritizes organic growth and is looking for the right opportunities for share repurchase, with a focus on maintaining flexibility [31][32]. Question: Product Trends and Distributor Feedback - There is a continued interest in immune-supporting products, and distributors are eager to return to in-person meetings [38][41]. Question: Virtual Meeting Platforms - The company is currently using popular platforms like Zoom and Webex for virtual meetings, which have been effective in reaching a wider audience [44][48]. Question: Active Nutrition Line Rollout - The rollout of the Active Nutrition line is planned for early next year, with a focus on regulatory compliance and market-specific launches [49].

® THE CELLULAR NUTRITION COMPANY and and and a state 177 al i 20 t 7 4,28 23 Key | --- | --- | --- | |-------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Management will make forward-looking statements | | | | during this presentation. Actual results could differ | | | | from those projected in such forward-looking | | | | --- | --- | --- | |----------------------------------------------------------------------------------------- ...

USANA Health Sciences Inc. (NYSE:USNA) Q2 2020 Results Conference Call July 22, 2020 11:00 AM ET Company Participants Patrique Richards - Executive Director, Investor Relations & Business Development Kevin Guest - Chairman & Chief Executive Officer Doug Hekking - Chief Financial Officer Conference Call Participants Steph Wissink - Jefferies Doug Lane - Lane Research Ivan Feinseth - Tigress Financial Partners Operator Good day and welcome to the USANA Health Sciences' Second Quarter Conference Call. Today's ...